AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29602430 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gamified website
Number of subjects: 151
Study 29602430 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 151
Study 28407264 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (3 separate 30-minute sessions)
Number of subjects: 14
Study 28407264 — intervention group
Group type: COMPARATOR
Intervention: Massed training (1 single 90-minute session)
Number of subjects: 14
Study 28407264 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Interval and Massed)
Number of subjects: 14
Study 26513991 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese traditional treatment after routine treatment
Number of subjects: 88
Study 26513991 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 88
Study 23884027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) for more than 10 years (group A)
Number of subjects: 250
Study 23884027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy (MBT) for 3 to 10 years (group B)
Number of subjects: 250
Study 23884027 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 250
Study 22010779 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR course (8-week mindfulness-based stress reduction course)
Number of subjects: 59
Study 22010779 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study 19240655 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) - 17beta‐estradiol (1 mg) with cyclic micronized progesterone (200 mg) for 10 days per month
Number of subjects: 23
Study 19240655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl amyl glycolate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl (cyclohexyloxy)acetate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl phenoxyacetate in 1:3 diethyl phthalate:ethanol at 2.0% concentration
Number of subjects: 129
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl amyl glycolate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl (cyclohexyloxy)acetate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129
Study 16717034 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl phenoxyacetate in diethyl phthalate vehicle at 2.0% concentration
Number of subjects: 129
Study 15538120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 402
Study 15538120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + Lithium (Li) or Divalproex (DVP)
Number of subjects: 402
Study 11379840 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission QWB subscales for physical and social activity
Number of subjects: 59
Study 11379840 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmark model including age at first depression, admission BDI score, and melancholia
Number of subjects: 59
Study 9403359 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylsergide and Propranolol (antagonists at 5-HT receptors)
Number of subjects: 390
Study 9403359 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine and Sumatriptan (5-HT1 agonists)
Number of subjects: 390
Study 8124228 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 0
Study 8124228 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 2459989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2, 3.5, and 5 million KIU)
Number of subjects: 40
Study 2459989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 40
Study 30318743 — intervention group
Group type: EXPERIMENTAL
Intervention: HNRMS survivors
Number of subjects: 65
Study 28855225 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber from diet (HFD)
Number of subjects: 19
Study 28855225 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber from supplement (HFS)
Number of subjects: 19
Study 28855225 — intervention group
Group type: COMPARATOR
Intervention: Usual fiber (UF)
Number of subjects: 19
Study 25970050 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102
Number of subjects: 800
Study 25970050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 22986445 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed treadmill with body weight support system (HST)
Number of subjects: 32
Study 22986445 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treadmill (ST) without body weight support system
Number of subjects: 32
Study 22986445 — intervention group
Group type: COMPARATOR
Intervention: Control group (NT)
Number of subjects: 32
Study 21531089 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 189
Study 21531089 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 189
Study 18579898 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise (STEX)
Number of subjects: 61
Study 18579898 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (PASS)
Number of subjects: 61
Study 18579898 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 61
Study 16783060 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 140
Study 16783060 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chemotherapy)
Number of subjects: 140
Study 15144931 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (maximum dose of 25 mg bid)
Number of subjects: 1959
Study 15144931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1959
Study 15144931 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 1959
Study 11056096 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 146
Study 11056096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 8886633 — intervention group
Group type: COMPARATOR
Intervention: Sodium tetradecyl sulfate (1.5% STS)
Number of subjects: 51
Study 8886633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose water (50% GW)
Number of subjects: 51
Study 1642222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus enteric‐coated charcoal (four tablets daily)
Number of subjects: 12
Study 1642222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine plus bismuth (30 ml Pepto‐Bismol four times daily)
Number of subjects: 12
Study 1642222 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine alone (300 mg at bedtime)
Number of subjects: 12
Study 1642222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg at bedtime) with all regimens
Number of subjects: 12
Study 6138315 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg orally)
Number of subjects: 13
Study 6138315 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg orally)
Number of subjects: 13
Study 6138315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30690653 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect-based Kaimai-style Qigong exercise
Number of subjects: 55
Study 30690653 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlisted)
Number of subjects: 55
Study 27323775 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH; T core 33°C‐34°C)
Number of subjects: 13
Study 27323775 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (NT; T core 36°C‐37°C)
Number of subjects: 13
Study 26012788 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential therapy (effective stimulation)
Number of subjects: 200
Study 26012788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham stimulation)
Number of subjects: 200
Study 24238769 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 12
Study 24238769 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 12
Study 21206386 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX (gemcitabine 1,000 mg/m on days 1 and 8 followed by oxaliplatin 130 mg/m on day 1 every 3 weeks)
Number of subjects: 371
Study 21206386 — intervention group
Group type: COMPARATOR
Intervention: PCb (paclitaxel 225 mg/m followed by carboplatin AUC = 6 on day 1 every 3 weeks)
Number of subjects: 371
Study 19036535 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana prevention program
Number of subjects: 257
Study 19036535 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 257
Study 19036535 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental marijuana use
Number of subjects: 257
Study 19036535 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental aggression
Number of subjects: 257
Study 17466657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release (12.5-62.5 mg/day)
Number of subjects: 116
Study 17466657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine (2 g/d)
Number of subjects: 30
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionylcarnitine (2 g/d)
Number of subjects: 30
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine + Propionylcarnitine
Number of subjects: 30
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Number of subjects: 30
Study 15039515 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionylcarnitine
Number of subjects: 30
Study 11478511 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily (group A)
Number of subjects: 80
Study 11478511 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 80
Study 9683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin treatment
Number of subjects: 20
Study 9683394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil treatment
Number of subjects: 20
Study 9683394 — intervention group
Group type: COMPARATOR
Intervention: Frozen yoghurt (control)
Number of subjects: 20
Study 7849232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (1 g administered intravenously over 3-5 min)
Number of subjects: 27
Study 7849232 — intervention group
Group type: EXPERIMENTAL
Intervention: GSP and MGEC tests
Number of subjects: 27
Study 3154472 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 369
Study 3154472 — intervention group
Group type: COMPARATOR
Intervention: AZ (Control)
Number of subjects: 369
Study 3154472 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell antibody positive cases
Number of subjects: 369
Study 3154472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold B-cell positive cases
Number of subjects: 369
Study 3154472 — intervention group
Group type: EXPERIMENTAL
Intervention: AZ and local graft irradiation
Number of subjects: 369
Study 30956039 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery (RS)
Number of subjects: 169
Study 30956039 — intervention group
Group type: EXPERIMENTAL
Intervention: Local excision (LE)
Number of subjects: 169
Study 30956039 — intervention group
Group type: EXPERIMENTAL
Intervention: Wait-and-see (WS)
Number of subjects: 169
Study 28572281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus only
Number of subjects: 3044
Study 28572281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both METS and Diabetes Mellitus
Number of subjects: 3044
Study 28572281 — intervention group
Group type: COMPARATOR
Intervention: Neither METS nor DM
Number of subjects: 3044
Study 28572281 — intervention group
Group type: COMPARATOR
Intervention: METS only
Number of subjects: 3044
Study 25236353 — intervention group
Group type: EXPERIMENTAL
Intervention: 7T MRI exposure
Number of subjects: 44
Study 25236353 — intervention group
Group type: COMPARATOR
Intervention: Mock scanner with no magnetic field
Number of subjects: 44
Study 23631804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (50,000 IU weekly for 8 weeks and 50,000 IU monthly for 10 months)
Number of subjects: 320
Study 23631804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 22151921 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteal intramuscular corticosteroid injection
Number of subjects: 135
Study 22151921 — intervention group
Group type: COMPARATOR
Intervention: Gluteal intramuscular placebo (saline) injection
Number of subjects: 135
Study 19673352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for three days (Group B)
Number of subjects: 3
Study 19673352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefteram pivoxil (CFTM‐PI) 300 mg, three times daily for five days (Group C)
Number of subjects: 3
Study 19673352 — intervention group
Group type: COMPARATOR
Intervention: No oral antimicrobial administration (Group A)
Number of subjects: 3
Study 17082283 — intervention group
Group type: EXPERIMENTAL
Intervention: A100 (4% articaine HCl with 1:100,000 epinephrine)
Number of subjects: 0
Study 17082283 — intervention group
Group type: COMPARATOR
Intervention: A200 (4% articaine HCl with 1:200,000 epinephrine)
Number of subjects: 0
Study 14677105 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Cohort Design (CCD)
Number of subjects: 0
Study 10776974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiorfan (racecadotril) 300 mg/day from D0 to D15
Number of subjects: 136
Study 10776974 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic treatment
Number of subjects: 136
Study 10776974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiorfan (racecadotril) 300 mg/day
Number of subjects: 136
Study 8942437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking, diabetes, high cholesterol, and hypertension in Mexican Americans
Number of subjects: 2629
Study 8942437 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking, diabetes, high cholesterol, and hypertension in non-Hispanic whites
Number of subjects: 2629
Study 1534528 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LCCE)
Number of subjects: 77
Study 1534528 — intervention group
Group type: COMPARATOR
Intervention: mini-lap cholecystectomy (mini-lap CCE)
Number of subjects: 77
Study 3939598 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Special Care Units (GSCUs)
Number of subjects: 0
Study 3939598 — intervention group
Group type: COMPARATOR
Intervention: Traditional adult medical/surgical unit
Number of subjects: 0
Study 31356535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.5-µg/kg overload dose for 10 minutes and a 0.5-μg/kg/h maintenance dose
Number of subjects: 28
Study 31356535 — intervention group
Group type: COMPARATOR
Intervention: Non-DEX (saline)
Number of subjects: 28
Study 31356535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 28
Study 29793345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT)
Number of subjects: 326
Study 29793345 — intervention group
Group type: COMPARATOR
Intervention: Standard Palliative Care (Control)
Number of subjects: 326
Study 29793345 — intervention group
Group type: COMPARATOR
Intervention: Client-Centered Care (Control)
Number of subjects: 326
Study 27552270 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS Total Worker Health intervention
Number of subjects: 149
Study 24951180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multifactorial interventions
Number of subjects: 300
Study 24951180 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle advice with continued conventional care (Control)
Number of subjects: 300
Study 22281837 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual coach intervention (automated, animated computer agent providing personalized feedback and goal setting)
Number of subjects: 70
Study 22281837 — intervention group
Group type: COMPARATOR
Intervention: Pedometer and website alone (control group)
Number of subjects: 70
Study 22281837 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual coach intervention
Number of subjects: 70
Study 22281837 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual coach intervention and control group
Number of subjects: 70
Study 20826253 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation pharmacotherapies
Number of subjects: 1504
Study 20826253 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intensity (cigarettes per day, pack-years, carbon monoxide, Fagerström Test of Nicotine Dependence)
Number of subjects: 1504
Study 20826253 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intensity (pack-years, cigarettes per day, carbon monoxide, Fagerström Test of Nicotine Dependence)
Number of subjects: 1504
Study 20826253 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference and triglycerides
Number of subjects: 1504
Study 18420471 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (120 U into the antrum and 80 U into the fundus)
Number of subjects: 30
Study 18420471 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 30
Study 15964595 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 18
Study 15964595 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 12943892 — intervention group
Group type: EXPERIMENTAL
Intervention: candesartan
Number of subjects: 73
Study 12943892 — intervention group
Group type: COMPARATOR
Intervention: lisinopril
Number of subjects: 73
Study 10220228 — intervention group
Group type: EXPERIMENTAL
Intervention: Real motor task (little and index finger abduction)
Number of subjects: 7
Study 10220228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental non‐motor activity (arithmetical calculation)
Number of subjects: 7
Study 10220228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental simulation of selective index finger or little finger abduction
Number of subjects: 7
Study 10220228 — intervention group
Group type: COMPARATOR
Intervention: Full muscular and mental relaxation
Number of subjects: 7
Study 7759438 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n = 6)
Number of subjects: 12
Study 7759438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 1983344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg q.d.s. for 1 week
Number of subjects: 0
Study 1983344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte for 1 week
Number of subjects: 0
Study 1983344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufotidine 300 mg b.d. for 1 week
Number of subjects: 0
Study 1983344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufotidine 600 mg b.d. for 14 days
Number of subjects: 0
Study 384248 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 68
Study 384248 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin
Number of subjects: 68
Study 31820601 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Jingtong granule
Number of subjects: 114
Study 31820601 — intervention group
Group type: COMPARATOR
Intervention: Jingtong granule (4 g, 3 times a day)
Number of subjects: 114
Study 27798369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 215
Study 27798369 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 215
Study 26156174 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of service users at strategic, site, and local levels in the SAFER 2 trial
Number of subjects: 0
Study 26156174 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional strategic level forums (Task and Finish Groups and Writing Days)
Number of subjects: 0
Study 23225093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and intracameral anesthesia without sedation during first eye surgery
Number of subjects: 60
Study 23225093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical and intracameral anesthesia without sedation during second eye surgery
Number of subjects: 60
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single or double dose of MF59-adjuvanted influenza A(H1N1) vaccine
Number of subjects: 80
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine (virosome-adjuvanted trivalent influenza vaccine)
Number of subjects: 80
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic vaccine
Number of subjects: 80
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Local adverse events at the injection site of pandemic vaccine
Number of subjects: 80
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Local adverse events at the injection site of seasonal vaccine
Number of subjects: 80
Study 21916971 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited systemic adverse events
Number of subjects: 80
Study 18699786 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA and 5% NaOCl
Number of subjects: 60
Study 18699786 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA and 2.5% NaOCl
Number of subjects: 60
Study 18699786 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 60
Study 18699786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 60
Study 18699786 — intervention group
Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 60
Study 16504463 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (CARDIO) 3 days/week, 45 min/day for 10 months
Number of subjects: 0
Study 16504463 — intervention group
Group type: COMPARATOR
Intervention: Flexibility/strength exercise (FLEX) 3 days/week, 45 min/day for 10 months
Number of subjects: 0
Study 12755970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen cream use
Number of subjects: 360